HS in Acute Lung Injury: a Therapeutic Dead End(?)
Overview
Authors
Affiliations
This review addresses the plausibility of hydrogen sulfide (HS) therapy for acute lung injury (ALI) and circulatory shock, by contrasting the promising preclinical results to the present clinical reality. The review discusses how the narrow therapeutic window and width, and potentially toxic effects, the route, dosing, and timing of administration all have to be balanced out very carefully. The development of standardized methods to determine in vitro and in vivo HS concentrations, and the pharmacokinetics and pharmacodynamics of HS-releasing compounds is a necessity to facilitate the safety of HS-based therapies. We suggest the potential of exploiting already clinically approved compounds, which are known or unknown HS donors, as a surrogate strategy.
Taghavi M, Tavanaei Tamanaei T, Oghazian M, Tavana E, Mollazadeh S, Niloofar P Curr Ther Res Clin Exp. 2023; 98:100699.
PMID: 36998289 PMC: 10011030. DOI: 10.1016/j.curtheres.2023.100699.
Denoix N, McCook O, Scheuerle A, Kapapa T, Hoffmann A, Gundel H Front Med (Lausanne). 2022; 9:925433.
PMID: 35847799 PMC: 9279570. DOI: 10.3389/fmed.2022.925433.
HS in Critical Illness-A New Horizon for Sodium Thiosulfate?.
Merz T, McCook O, Brucker C, Waller C, Calzia E, Radermacher P Biomolecules. 2022; 12(4).
PMID: 35454132 PMC: 9029606. DOI: 10.3390/biom12040543.
Understanding Cellular Redox Homeostasis: A Challenge for Precision Medicine.
Tretter V, Hochreiter B, Zach M, Krenn K, Klein K Int J Mol Sci. 2022; 23(1).
PMID: 35008532 PMC: 8745322. DOI: 10.3390/ijms23010106.
Merz T, McCook O, Denoix N, Radermacher P, Waller C, Kapapa T Int J Mol Sci. 2021; 22(17).
PMID: 34502097 PMC: 8430789. DOI: 10.3390/ijms22179192.